MedTrace Logo

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

NCT01296191 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-12-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare drug concentrations in aqueous humor following ocular instillation of Besivance and VIGAMOX in subjects undergoing cataract surgery.

Conditions

  • Cataracts

Interventions

DRUG

Moxifloxacin

One drop 4 times daily for 3 days and one drop the day of sample collection

DRUG

besifloxacin

One drop 4 times daily for 3 days and one drop on day of sample collection

Sponsors & Collaborators

  • Frank A. Bucci, Jr., M.D.

    lead OTHER

Principal Investigators

  • Frank A. Bucci, Jr., MD · Bucci Laser Vision Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01296191 on ClinicalTrials.gov